Background
==========

Traditionally, patients with liver cirrhosis have an auto-anticoagulation status because they often have an elevated prothrombin time (PT) or international normalized ratio (INR) \[[@b1-medscimonit-22-969]--[@b4-medscimonit-22-969]\]. If so, a cirrhotic patient should rarely experience thrombotic events. However, the accumulated evidence suggests that cirrhotic patients have an increased risk of venous thromboembolism (VTE), which is defined as deep vein thrombosis (DVT) and pulmonary embolism (PE) \[[@b5-medscimonit-22-969]--[@b25-medscimonit-22-969]\]. Case-control studies have also confirmed that cirrhotic patients are more likely to develop VTE than the general population \[[@b26-medscimonit-22-969]\]. Our recent systematic review and meta-analysis found that about 1% of patients with chronic liver diseases had and developed VTE during their hospitalizations \[[@b27-medscimonit-22-969]\]. However, the relevant data are almost all from Western countries; by comparison, few studies have been conducted in Chinese populations. The most common etiology of liver cirrhosis was hepatitis B virus in China \[[@b28-medscimonit-22-969]\]. On the other hand, there was no consensus about the risk factors of VTE in liver cirrhosis. Herein, we conducted a retrospective observational study to evaluate the epidemiology and risk factors of VTE in Chinese hospitalized patients with liver cirrhosis and to explore whether VTE might influence the in-hospital mortality of liver cirrhosis.

Material and Methods
====================

In this retrospective observational study, all patients with a diagnosis of liver cirrhosis who were consecutively admitted to the General Hospital of Shenyang Military Area between January 2011 and December 2013 were identified by searching the international classification codes (ICD)-9, ICD-10, and discharge diagnoses in the Department of Information. Diagnosis of liver cirrhosis was primarily established according to the history of liver disease, clinical presentations, laboratory tests, and abdominal imaging. Patients with malignancy were excluded. Repeated admission was not excluded. Some patients had been included in our previous studies \[[@b29-medscimonit-22-969]--[@b32-medscimonit-22-969]\]. The study protocol was approved by the Ethics Committee of our hospital The number was K(2015)30. Informed written consents were waived.

VTE was defined as DVT and PE. Considering that the potential pathogenesis and prognosis might be different between VTE and portal venous system thrombosis \[[@b33-medscimonit-22-969],[@b34-medscimonit-22-969]\], portal venous system thrombosis was not considered in the present study. The medical records were thoroughly searched by an investigator to identify the history and new onset of VTE (XZ). The data accuracy was checked by another investigator (XQ). Diagnosis of VTE was established according to the clinical presentations and imaging examinations.

Additional data were collected by our study group, including the age, sex, blood pressure at admission, history of liver cirrhosis, etiology of liver disease, acute gastrointestinal bleeding (AUGIB), ascites, hepatic encephalopathy, and laboratory tests (red blood cell count, hemoglobin, white blood cell count, platelets, total bilirubin, albumin, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, glutamyl transpeptidase, blood urea nitrogen, creatinine, potassium, sodium, PT/INR, activated partial thromboplastin time, and D-dimer). Arterial hypertension was classified into grade I, II, and III according to the guideline \[[@b35-medscimonit-22-969]\]. Ascites and hepatic encephalopathy were graded according to the guidelines \[[@b36-medscimonit-22-969],[@b37-medscimonit-22-969]\]. Child-Pugh and model for end-stage liver diseases (MELD) scores were calculated according to the previous criteria \[[@b38-medscimonit-22-969],[@b39-medscimonit-22-969]\]. In-hospital death was reviewed. Causes of death were also recorded.

Statistical analysis
--------------------

All statistical analyses were performed by SPSS Statistics version 17.0.0. Continuous data are expressed as mean ± standard deviation and median with range and were compared by the independent sample *t* test. Categorical data were expressed as frequency (percentage) and were compared by the chi-square test or Fisher exact test. A bar chart was also drawn to compare the in-hospital mortality between patients with and without VTE. Two-sided p\<0.05 was considered to be statistically significant.

Results
=======

Patients
--------

Overall, 2006 patients were included in our study. A majority of patients were male, had hepatitis B virus and alcohol abuse, and had Child-Pugh class A and B ([Table 1](#t1-medscimonit-22-969){ref-type="table"}). Among them, 5 patients had a previous history of lower extremity DVT, 1 patient had a previous history of lower extremity DVT and developed new onset of PE during hospitalization, 1 patient developed new onset of PE during hospitalization, and 2 patients developed new onset of DVT during hospitalization. Thus, the prevalence of VTE in liver cirrhosis during hospitalization was 0.4% (9/2006) and the incidence of VTE was 0.2% (4/2006).

Comparison between patients with and without VTE
------------------------------------------------

Compared with those without VTE, patients with VTE had a significantly higher proportion of hypertension and significantly higher red blood cells, hemoglobin, alanine aminotransferase, aspartate aminotransferase, PT, INR, D-dimer, and Child-Pugh scores ([Table 1](#t1-medscimonit-22-969){ref-type="table"}). MELD score was statistically similar between the 2 groups.

In-hospital mortality between patients with and without VTE
-----------------------------------------------------------

The in-hospital mortality was 3.5% (70/2006). Causes of death are shown in [Table 2](#t2-medscimonit-22-969){ref-type="table"}. The in-hospital mortality was significantly higher in patients with VTE than in those without VTE (33.3% \[3/9\] versus 3.4% \[67/1997\], P\<0.001) ([Figure 1](#f1-medscimonit-22-969){ref-type="fig"}). The overall mortality due to VTE was 0.09% (2/2006) and VTE accounted for 2.8% of all causes of death (2/70).

Discussion
==========

Our study demonstrated that the prevalence and incidence of VTE during hospitalization was 0.4% and 0.2% in Chinese patients with liver cirrhosis, respectively. This finding was relatively lower than our recent systematic review that the incidence of VTE in patients with chronic liver diseases was 1% (95% confidence interval: 0.7--1.3%), and the prevalence of VTE was 1% (95% confidence interval: 0.7--1.2%) \[[@b27-medscimonit-22-969]\]. This discrepancy might be explained by the heterogeneous sample size and etiology of liver cirrhosis among studies; despite this, we preferred to emphasize another major finding -- that patients with VTE had an approximately 10-fold higher risk of in-hospital death than those without VTE. Certainly, a small number of patients with VTE might restrict the interpretation of comparative analysis. Considering a statistically significant difference of in-hospital mortality between the 2 groups, we had to acknowledge the importance of early diagnosis and treatment of VTE in liver cirrhosis.

We also attempted to analyze the risk factors for VTE in liver cirrhosis. D-dimer, red blood cells, hemoglobin, alanine aminotransferase, aspartate aminotransferase, PT, INR, and Child-Pugh scores were significantly associated with the presence of VTE. Except for D-dimer, which has been a routine diagnostic test for VTE \[[@b40-medscimonit-22-969]\], and arterial hypertension, which is an important determinant of VTE in the general population \[[@b41-medscimonit-22-969]\], the risk factors for VTE should be interpreted carefully. First, patients with VTE had significantly higher red blood cell and hemoglobin than those without VTE, possibly because none of patients with VTE had AUGIB, but 28.3% of patients without VTE had AUGIB. Thus, we might speculate that AUGIB was rarely complicated in patients with VTE. Second, patients with VTE had significantly higher alanine aminotransferase and aspartate aminotransferase than those without VTE. Similarly, patients with VTE also had significantly higher Child-Pugh scores than those without VTE. Additionally, higher total bilirubin and lower albumin were observed in patients with VTE, but the difference was not statistically significant. Thus, the relationship between severity of liver dysfunction and probability of VTE is suggested. Third, patients with VTE had significantly higher PT and INR than those without VTE. This finding is seemingly counterintuitive, but was largely consistent with the modern concept that PT and INR do not reflect the global coagulation status, and that elevated PT and INR does not protect cirrhotic patients from the development of VTE. This has been repeatedly reported in previous studies and was recently reviewed \[[@b42-medscimonit-22-969]--[@b44-medscimonit-22-969]\]. This finding can be explained by the fact that PT and INR mirror the liver synthesis of the procoagulants only, whereas other parameters associated with an overall decrease of liver function can be more accurate surrogates for impaired production of procoagulants as well as natural anticoagulants.

Except for our findings, previous studies should be deeply and systematically discussed. We described a detailed search strategy in our recent systematic review of the epidemiology of VTE in liver diseases \[[@b27-medscimonit-22-969]\]. Studies were eligible if they compared the characteristics between liver disease patients with and without VTE. Notably, we just summarized the risk factors of VTE in the patients with liver diseases, but not in the general population. Indeed, in the latter condition, the presence of liver disease might be one of the variables included. Thus, the following items about the risk factors of VTE were collected: variables included in the univariable analyses, significant factors calculated in the univariate analyses, the variables included in the multivariate analyses, and the independent predictors calculated in the multivariate analyses. Their frequencies were counted. The odds or risk ratio for each factor was also recorded to clarify whether the independent factors increased or decreased the risk of VTE in liver diseases.

Overall, 7 individual studies evaluated the risk factors of predicting the development of VTE in patients with liver diseases in univariate analyses, and 5 of them also conducted multivariate analyses \[[@b7-medscimonit-22-969],[@b9-medscimonit-22-969],[@b11-medscimonit-22-969],[@b12-medscimonit-22-969],[@b18-medscimonit-22-969],[@b19-medscimonit-22-969],[@b24-medscimonit-22-969]\] ([Table 3](#t3-medscimonit-22-969){ref-type="table"}). A total of 19 significant risk factors were reported in univariate analyses. They included age, race, Charlson co-morbidity index, insurance, encephalopathy, variceal bleeding, ascites, coagulopathy, hypo-osmolality, malnutrition, total parenteral nutrition, mechanical ventilation, central venous line placement, diabetes mellitus, albumin, creatinine, aspartate aminotransferase, alanine aminotransferase, and hematocrit. A total of 16 independent risk factors were reported in multivariate analyses. The race with the highest risk of VTE was black, followed by white and Hispanics. A higher Charlson co-morbidity index, malnutrition, central venous line placement, active malignancy, trauma or surgery during hospitalization, history of VTE, and diabetes mellitus were also associated with an increased risk of VTE in patients with liver diseases. The presence of encephalopathy, variceal bleeding, ascites, coagulopathy, and hypo-osmolality, Medicaid insurance, and use of VTE prophylaxis were associated with a decreased risk of VTE.

A lower albumin level was identified as an independent predictor of VTE in 2 studies by Northup \[[@b19-medscimonit-22-969]\] and Walsh \[[@b24-medscimonit-22-969]\]. In the study by Northup, the albumin level was significantly lower in cirrhotic patients with VTE than in those without VTE (mean: 2.85 g/dL, 95%CI: 2.70--3.01 versus mean: 3.10 g/dL, 95%CI: 2.96--3.23, P=0.01); in the study by Walsh, the albumin level was significantly lower in patients with VTE than in those without VTE (median: 2.1 g/dL, interquartile range: 1.7--2.6 versus median: 2.4 g/dL, interquartile range: 2--2.8, P=0.02). By contrast, another two studies did not identify the albumin level as a significant predictor of VTE in the multivariate analyses \[[@b11-medscimonit-22-969],[@b18-medscimonit-22-969]\]. In the study by Lesmana, the proportion of an albumin level \<3 mg/dL was lower in patients with DVT than in those without DVT (75% \[9/12\] versus 49.2% \[120/244\], P=0.081), but the difference was not statistically significant. No detailed data was reported in the study by Barclay.

Although a firm conclusion was not achieved, these preliminary findings from our team and others are helpful for the identification of high-risk patients. However, these data were scattered and needed to be integrated into a score system or predictive index. Ideally, a prospective study should include a training cohort to produce a predictive model to stratify the risk of the development of VTE and a validation cohort to confirm its accuracy.

The retrospective nature was a major limitation of our study. Although we selected all patients consecutively admitted to our hospital and had very few exclusion criteria, the patient selection bias should not be neglected in a retrospective study. Second, laboratory and radiological examinations for the diagnosis of VTE were not routinely performed. Prospective studies might be warranted to establish the accurate epidemiology of VTE, especially asymptomatic VTE. Third, the regional and ethnic difference in the epidemiology of VTE could not be evaluated in this single-center study.

Conclusions
===========

VTE was observed in 0.4% of patients with liver cirrhosis during hospitalization and it significantly increased the in-hospital mortality. Degree of liver dysfunction might be significantly associated with the presence of VTE in liver cirrhosis. More importantly, elevated PT/INR did not protect from the development of VTE, but increased the risk of VTE in liver cirrhosis. Due to potential study limitations, these findings should be cautiously interpreted and further validated.
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###### 

Patients characteristics.

  Variables                                        All patients (n=2006)   VTE in total (n=9)                   No VTE in total (n=1997)   P value                                                                           
  ------------------------------------------------ ----------------------- ------------------------------------ -------------------------- ------------------------------------- ------ ------------------------------------ ---------------
  Age (years)                                      2006                    56.24±12.18; 55.78 (6.20--95.13)     9                          56.94±13.36; 56.50 (40.07--84.35)     1997   56.23±12.18; 55.77 (6.20--95.13)     0.862
  Sex (male/female), n (%)                         2006                    1330 (66.3%)/ 676 (33.7%)            9                          8 (88.9%)/ 1 (11.1%)                  1997   1322 (66.2%)/ 675 (33.8%)            0.151
  History of liver cirrhosis, n (%)                1897                                                         8                                                                1889                                        0.184
   \<1 year                                                                690 (36.4%)                                                     5 (62.5%)                                    685 (36.3%)                          
   1--5 year                                                               769 (40.5%)                                                     3 (37.5%)                                    766 (40.6%)                          
   \>5 year                                                                438 (23.1%)                                                     0 (0.0%)                                     438 (23.2%)                          
  Causes of liver diseases, n (%)                  1999                                                         8                                                                1991                                        0.991
   HBV alone                                                               565 (28.3%)                                                     4 (50.0%)                                    561 (28.2%)                          
   HCV alone                                                               140 (7.0%)                                                      0 (0.0%)                                     140 (7.0%)                           
   HBV+HCV                                                                 13 (0.7%)                                                       0 (0.0%)                                     13 (0.7%)                            
   Alcohol alone                                                           492 (24.6%)                                                     2 (25.0%)                                    490 (24.6%)                          
   HBV + alcohol                                                           138 (6.9%)                                                      0 (0.0%)                                     138 (6.9%)                           
   HCV + alcohol                                                           20 (1.0%)                                                       0 (0.0%)                                     20 (1.0%)                            
   HBV + HCV + alcohol                                                     5 (0.3%)                                                        0 (0.0%)                                     5 (0.3%)                             
   Autoimmune                                                              83 (4.2%)                                                       0 (0.0%)                                     83 (4.2%)                            
   Drug                                                                    31 (1.6%)                                                       0 (0.0%)                                     31 (1.6%)                            
   Cholestatic                                                             54 (2.7%)                                                       0 (0.0%)                                     54 (2.7%)                            
   Others                                                                  28 (1.4%)                                                       0 (0.0%)                                     28 (1.4%)                            
   Unknown                                                                 428 (21.4%)                                                     2 (25.0%)                                    426 (21.4%)                          
   HBV + PBC                                                               2 (0.1%)                                                        0 (0.0%)                                     2 (0.1%)                             
  Blood pressure at admission, n (%)               1990                                                         8                                                                1982                                        ***\<0.001***
   Normal range                                                            1552 (78.0%)                                                    4 (50.0%)                                    1548 (78.1%)                         
   Hypotension                                                             51 (2.6%)                                                       0 (0.0%)                                     51 (2.6%)                            
   Hypertension -- Grade I                                                 274 (13.8%)                                                     2 (25.0%)                                    272 (13.7%)                          
   Hypertension -- Grade II                                                85 (4.3%)                                                       2 (25.0%)                                    83 (4.2%)                            
   Hypertension -- Grade III                                               28 (1.4%)                                                       0 (0.0%)                                     28 (1.4%)                            
  AUGIB, n (%)                                     1994                    563 (28.2%)                          8                          0 (0.0%)                              1986   563 (28.3%)                          0.075
  Ascites, n (%)                                   1991                                                         8                                                                1983                                        0.077
   No                                                                      1023 (51.4%)                                                    1 (12.5%)                                    1022 (51.5%)                         
   Mild                                                                    217 (10.9%)                                                     2 (25.0%)                                    215 (10.8%)                          
   Moderate and severe                                                     751 (37.7%)                                                     5 (62.5%)                                    746 (37.6%)                          
  Hepatic encephalopathy, n (%)                    1991                                                         8                                                                1983                                        0.733
   No                                                                      1848 (92.8%)                                                    8 (100.0%)                                   1840 (92.8%)                         
   Grade I--II                                                             117 (5.9%)                                                      0 (0.0%)                                     117 (5.9%)                           
   Grade II--IV                                                            26 (1.3%)                                                       0 (0.0%)                                     26 (1.3%)                            
  Red blood cell (10^12^/L)                        1960                    3.11±0.86; 3.07 (0.93--6.78)         9                          3.67±0.74; 3.41 (2.89--5.19)          1951   3.11±0.86; 3.06 (0.93--6.78)         ***0.049***
  Hemoglobin (g/L)                                 1960                    95.01±30.03; 93.00 (23.0--218.0)     9                          118.03±19.99; 121.00 (91.0--155.0)    1951   94.91±30.03; 93.00 (23.0--218.0)     ***0.021***
  White blood cell (109/L)                         1961                    5.40±4.14; 4.20 (0.30--46.10)        9                          7.02±4.26; 6.40 (3.20--17.00)         1952   5.39±4.13; 4.20 (0.30--46.10)        0.238
  Platelet (109/L)                                 1959                    100.97±86.83; 76.00 (5--1278)        9                          75.22±45.91; 57.00 (28--180)          1950   101.09±86.96; 76.00 (5--1278)        0.373
  Total bilirubin (umol/L)                         1926                    39.47±59.63; 21.85 (1.9--707.7)      9                          62.20±87.84; 33.10 (3.4--285.6)       1917   39.36±59.48; 21.80 (1.9--707.7)      0.252
  Albumin (g/L)                                    1901                    32.14±6.90; 32.10 (0.4--52.8)        9                          29.36±8.06; 33.00 (17.4--39.7)        1892   32.15±6.89; 32.10 (0.4--52.8)        0.225
  Alanine aminotransferase (U/L)                   1925                    39.35±65.78; 26.00 (3.0--1460)       9                          180.67±434.01; 29.00 (9.0--1335.0)    1916   38.69±58.87; 26.00 (3.0--1460)       ***\<0.001***
  Aspartate aminotransferase (U/L)                 1924                    57.48±102.45; 36.00 (8.0--2454)      9                          227.00±434.75; 55.00 (17.0--1366.0)   1915   56.68±98.08; 36.00 (8.0--2454)       ***\<0.001***
  Alkaline phosphatase (U/L)                       1921                    113.70±96.58; 86.00 (12.8--980.0)    9                          108.31±60.28; 89.00 (41.0--215.0)     1912   113.73±96.72; 86.00 (12.8--980.0)    0.867
  Glutamyl transpeptidase (U/L)                    1916                    113.92±202.34; 48.00 (1.5--4562)     9                          52.67±24.54; 59.00 (8.0--84.0)        1907   114.21±202.77; 48.00 (1.5--4562)     0.363
  Blood urea nitrogen (mmol/L)                     1881                    7.97±7.01; 5.89 (1.42--76.02)        9                          6.97±4.03; 6.14 (2.96--16.36)         1872   7.97±7.02; 5.89 (1.42--76.02)        0.669
  Creatinine (umol/L)                              1880                    87.16±116.78; 60.00 (2.8--1473)      9                          75.56±41.15; 63.00 (48.0--182.0)      1871   87.22±117.03; 60.00 (2.8--1473)      0.765
  Potassium (mmol/L)                               1910                    4.08±0.54; 4.04 (2.20--7.87)         9                          4.31±0.61; 4.10 (3.84--5.11)          1901   4.08±0.54; 4.04 (2.20--7.87)         0.184
  Sodium (mmol/L)                                  1909                    138.15±4.49; 138.80 (116.3--160.8)   9                          136.12±5.21; 137.30 (125.7--142.2)    1900   138.16±4.48; 138.80 (116.3--160.8)   0.175
  Prothrombin time (second)                        1881                    16.25±4.64; 15.20 (10.5--94.6)       9                          19.97±6.57; 19.20 (12.7--31.8)        1872   16.23±4.63; 15.20 (10.5--94.6)       ***0.016***
  Activated partial thromboplastin time (second)   1879                    43.18±11.92; 41.50 (20.0--180.0)     9                          45.70±18.91; 40.10 (28.3--87.3)       1870   43.17±11.89; 41.50 (20.0--180.0)     0.526
  International normalized ratio                   1875                    1.34±0.57; 1.20 (0.76--13.40)        8                          1.75±0.82; 1.53 (0.98--3.22)          1867   1.33±0.57; 1.20 (0.76--13.40)        ***0.039***
  D-dimer (ug/ml)                                  609                     0.76±1.32; 0.30 (0--15.5)            4                          5.75±6.86; 3.60 (0.3--15.5)           605    0.73±1.17; 0.30 (0--9.0)             ***0.022***
  Child-Pugh score                                 1781                    7.53±2.04; 7.00 (5--15)              7                          9.14±1.68; 9.00 (6--11)               1774   7.53±2.04; 7.00 (5--15)              ***0.037***
  Child-Pugh class, n (%)                          1781                                                         7                                                                1774                                        0.437
   A                                                                       649 (36.4%)                                                     1 (14.3%)                                    648 (36.5%)                          
   B                                                                       827 (46.4%)                                                     4 (57.1%)                                    823 (46.4%)                          
   C                                                                       305 (17.1%)                                                     2 (28.6%)                                    303 (17.1%)                          
  MELD score                                       1794                    7.40±7.48; 5.96 (−14.28--51.64)      7                          12.41±10.48; 10.53 (−1.16--26.40)     1787   7.38±7.47; 5.95 (−14.28--51.64)      0.076

HBV -- hepatitis B virus; HCV -- hepatitis C virus; PBC -- primary biliary cirrhosis; AUGIB -- acute upper gastrointestinal bleeding; MELD -- model for end stage liver disease.

###### 

Causes of in-hospital death.

  Causes                                                          All patients   VTE in total   No VTE in total
  --------------------------------------------------------------- -------------- -------------- -----------------
  Massive gastrointestinal bleeding                               23             0              23
  Liver failure                                                   12             1              11
  Liver failure plus multiple organ failure                       11             0              11
  Multiple organ failure                                          7              0              7
  Massive gastrointestinal bleeding plus multiple organ failure   4              0              4
  Pulmonary embolism                                              2              2              0
  Renal failure                                                   2              0              2
  Sudden cardiac arrest                                           2              0              2
  Cerebral infarction plus multiple organ failure                 2              0              2
  Cerebral infarction plus massive gastrointestinal bleeding      1              0              1
  Massive gastrointestinal bleeding plus liver failure            1              0              1
  Respiratory failure                                             1              0              1
  Sepsis                                                          1              0              1
  Severe pulmonary infection                                      1              0              1

###### 

Summary of univariate and multivariate analyses regarding the risk factors of VTE in liver diseases.

  First author, journal (year)            Univariate analysis   No. observed/significant variables in univariate analyses   Multivariate analysis   No. observed/significant variables in multivariate analyses
  --------------------------------------- --------------------- ----------------------------------------------------------- ----------------------- -------------------------------------------------------------
  Aldawood A, Thromb J (2011)             Yes                   29/0                                                        No                      Not applicable
  Ali M, Dig Dis Sci (2011)               Yes                   22/13                                                       Yes                     10/10
  Barclay SM, Pharmacotherapy (2013)      Yes                   4/0                                                         Yes                     8/4
  Dabbagh O, Chest (2010)                 Yes                   3/0                                                         No                      Not applicable
  Lesmana CRA, Hepatol Int (2010)         Yes                   17/1                                                        Yes                     4/1
  Northup PG, Am J Gastroenterol (2006)   Yes                   13/1                                                        Yes                     5/1
  Walsh KA, Ann Pharmacother (2013)       Yes                   18/5                                                        Yes                     7/1
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